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Objectives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) versus 
other subcutaneous (SC) anti-tumour necrosis factors (anti-TNFs) currently licensed 
and reimbursed in Romania (etanercept [ETA] and adalimumab [ADA]) in the treat-
ment of adult patients with active rheumatoid arthritis (RA), axial spondyloarthri-
tis (axSpA; comprising ankylosing spondylitis [AS] and non-radiographic axSpA 
[nr-axSpA]) and psoriatic arthritis (PsA). MethOds: Cost-utility models (Markov 
structure) were developed for each condition, following the EULAR, ASAS and NICE 
guidelines. Clinical efficacy data, disease history and resource use data came from 
published literature. Utilities were derived from EQ-5D data assessed in CZP piv-
otal clinical trials. Published 2013 unit costs were taken from local sources/expert 
opinion. A willingness-to-pay threshold of 3xGDP/capita (87600RON) was consid-
ered. Base-case analysis was conducted from the payer perspective, with lifetime 
horizon, costs and outcomes discounting rates of 3.5%. Sensitivity analyses were 
conducted to test the robustness of the results. Results: In AS, CZP dominates 
ADA and ETA (quality-adjusted life years [QALYs] gain of 0,098 and 0,021; total costs 
lower by 48499.73RON and 8350.28RON, vs ADA and ETA respectively). In nr-axSpA, 
CZP dominates ADA (QALYs gain of 0,257; total costs lower by 13955.14RON). In RA, 
CZP dominates ADA (QALY gain of 0,226; total costs lower by 108694RON) and is 
marginally as effective, but slightly more costly vs ETA (QALYs gain of 0,056, total 
costs higher by 6356RON). In PsA, CZP dominates ADA (QALY gain of 0.05; total 
costs lower by 9397RON) and is less costly, but marginally less effective versus ETA 
(QALYs difference of -0.08, total costs lower by 21484RON). Probabilistic sensitivity 
analysis indicated that CZP has a similar or higher probability of being cost-effective 
when compared to comparators. cOnclusiOns: CZP is a cost-effective treatment 
compared to currently available SC anti-TNFs for the treatment of RA, axSpA and 
PsA in Romania.
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Objectives: Osteoporosis is a condition consisting in reduced bone mass and 
density, thus resulting in an increased risk of fragility fractures. Considering the 
aforementioned, and in conjunction with the complications that osteoporosis 
engenders, a considerable economic burden is imposed on industrialized coun-
tries. The purpose of this study was to determine the thresholds at which treat-
ment initiation becomes cost-effective in Greece, using the fracture risk assessment 
algorithm (FRAX®) developed by WHO and recently adjusted for Greece. MethOds: 
A previously developed state transition Markov model was populated employing 
epidemiological and economic data from Greece. The analysis calculated the cost-
effective intervention thresholds using the Greek FRAX® model, which estimates 
the 10-year probability of a major osteoporotic fracture in subjects with a fracture 
risk equivalent to that of a woman with a prior fragility fracture and no other risk 
fracture. The analysis was undertaken from a third-party payer perspective, assum-
ing a willingness to pay of 30,000€ per QALY gained. Results: In Greece, the drug 
intervention aiming at reducing the fracture risk, was found to be cost-effective 
with a 10-year probability for a major osteoporotic fracture at/or above 12.3% (range: 
7.8%-20.4%) for women and 18.2% (range: 9.6%-34.2%) for men aged from 50 to 59 
years old. When considering women and men aged between 60 and 74 years, the 
threshold was estimated ≥ 8.9% (range: 8.5%-9.2%) and ≥ 9.4% respectively (range: 
8.9%-10.0%), whereas for women and men over 75 years old, the cost-effective 
thresholds were calculated to be ≥ 15.0% (range: 13.0% to 16.0%) and ≥ 11.0% (range: 
10.6%-11.2%) accordingly. Significant age-variations were generally not noticed, 
some exceptions apart, especially for the age-range of 50-55. cOnclusiOns: As 
expected, the cost-effective thresholds obtained via FRAX® were age-dependent in 
both sexes. Therefore, considering these thresholds should lead to cost-effective 
access to therapy of patients with high fracture probability, and ipso facto signifi-
cantly reduce the economic burden of osteoporotic fractures in Greece.
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Objectives: Treat Osteoarthritis (OA) with traditional non-steroidal anti-inflamma-
tory drugs (t-NSAIDs) may be associated with significant gastrointestinal (GI) and 
cardiovascular (CV) events. The objective was to assess the cost-effectiveness (CE) 
of Celecoxib and non selective non steroidal anti-inflammatory drugs therapy for 
the treatment of OA in clinical practice in Spain. MethOds: The CE was assessed 
in patients aged 55+ years with OA and was based on a retrospective decision-tree 
model using distribution, dose and duration of therapies and incidence of GI and 
CV events observed in the pragmatic PROBE-designed 6-month “GI Reasons” trial. 
Effectiveness was expressed in terms of event averted and quality-adjusted life-
years (QALYs) gained. Utility loss in case of adverse events both in values and time 
duration were derived from the published literature. Perspective of the analysis 
was that of the National Health System (NHS) in Spain; cost calculations included 
actual prices of drugs plus cost of adverse events occurred during trial only. The 
analysis was expressed as an incremental CE ratio (ICER) per QALY gained and per 
event averted. Probabilistic and univariate sensitivity analyses, including celecoxib-
price-threshold analysis, were carried out. Results: Data from 7,939 patients were 
included in the analysis. Compared with traditional NSAIDs, celecoxib treatment 
had higher drug costs than traditional NSAIDs (€ 119 vs. € 34), and the overall treat-
ment cost was estimated at € 201 and € 157, respectively. Moreover, celecoxib was 
associated with slightly increase in QALY gain and significant lower incidence of 
gastrointestinal events (p< 0.001) with mean ICERs of € 13,286 per QALY gained and 
after initiating treatment that triggered treatment switching to subsequent thera-
pies upon failure. Scenario 1 compared a treatment sequence of a high efficacy 
biologic therapy followed by conventional DMARD therapy versus a less efficacious 
biologic therapy followed by a cDMARD. Scenario 2 compared two multiple biologic 
treatment sequences with a difference in efficacy between the first biologic in each 
sequence. A sensitivity analysis and a CE efficiency frontier analysis examined the 
effect of varying the difference in DAS-28 < 2.6 rates (Δ Rem) between first-line 
therapies. Results: In scenario 1, a Δ Rem of 10% between the bDMARDs yielded 
a mean per-patient gain of 0.117 QALYs and a mean per-patient increase in total 
cost £2,590, giving an incremental cost-effectiveness ratio (ICER) of £22,112 per 
QALY. In scenario 2, the higher efficacy bDMARD strategy had an ICER of £6,720 
when Δ Rem = 10%. cOnclusiOns: Over a lifetime, treating to the target of DAS-
28< 2.6 with more efficacious therapies in RA patients was cost-effective at various 
levels of efficacy differences. The higher costs of longer term treatment were offset 
by the increased quality of life for patients with DAS-28 < 2.6 as well as reduced 
hospitalisation costs.
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Objectives: Routine testing for HLA-B*5801 in European patients has been pro-
posed before allopurinol treatment aiming to reduce the incidence of Stevens-
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Having some discretion 
in the allocation of financial resources, Portuguese NHS hospitals may be particu-
larly interested in this issue as extra costs with the treatment of SJS/TEN episodes 
may be avoided. This study aims to evaluate the cost-effectiveness of HLA-B*5801 
genotyping versus no genotyping (usual care) in Portuguese adult patients newly 
diagnosed with gout before allopurinol treatment. MethOds: A decision tree model 
was constructed to structure the sequences of clinical events that may occur after 
the diagnosis of the disease, over a period of three months. Effectiveness data were 
estimated for Portuguese patients based on published literature and Portuguese 
population databases. All costs were obtained from official prices published for 
the Portuguese NHS. Admitting that NHS hospitals objective is to lower costs in the 
treatment of gout, the incremental cost per SJS/TEN reaction avoided was the incre-
mental cost-effectiveness ratio (ICER) considered. One way sensitivity analysis was 
performed for each relevant parameter. Results: The use of HLA-B*5801 genotyp-
ing versus no genotyping was associated with a decrease of 1.24 SJS/TEN reactions 
and an incremental total cost of 42, 401.03€ , resulting in an ICER of 34, 194.38€ per 
SJS/TEN reaction avoided. Sensitivity analysis results showed that base-case results 
are very sensitive to variations in the baseline odds ratio of gene-disease associa-
tion, epidemiological data used to estimate the incidence of SJS/TEN and genotyp-
ing cost. cOnclusiOns: Widespread use of HLA-B*5801 genotyping in Portuguese 
hospitals is not cost-effective at the current unit price of 45.30€ as it leads to a 
substantial increase in expenditure compared to usual care. However, it may be an 
advantageous option if its maximum price would equal 6,37€ .
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Objectives: The purpose of present study was to evaluate the cost-effectiveness of 
tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid 
arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime 
horizon in Kazakhstan. MethOds: A decision analytic model was constructed in 
MS-Excel to estimate effects and directs costs of methotrexate (MTX) combination 
with TCZ or IFX in hypothetical cohorts of RA patients. Treatment efficacy and 
transition probabilities were synthesized through a meta-analysis of data from 
relevant clinical trials and literature. The characteristics of patient cohort and treat-
ment costs (drug, monitoring, RA-related hospitalisation, adverse effects manage-
ment) in year 2014 Kazakhstani tenge (KZT) were estimated from republican official 
sources. Primary efﬁcacy outcome was deﬁned as an improvement of 70% in ACR 
response (ACR70), which can be regarded as a close measure of remission. Annual 
3% discounting rate and 6-month cycles were utilized for the model. Robustness of 
the model parameters was explored by one-way and probabilistic sensitivity analy-
sis. Results: For an average 70-kg patient, discounted direct costs per year were 
estimated at 4 456 000 KZT for TCZ+MTX and 3 190 000 KZT for IFX+MTX. Adjusted 
ACR70 rates were higher in TCZ+MTX group (23%) than in IFX+MTX group (17%). As 
a result of a lifetime stimulation (average 12 years) of the model, TCZ incurred 1.89 
times higher costs, and 1.67 times more achievements of ACR70 than IFX. The ICER 
was estimated to be 3 218 900 KZT per achieved ACR70, which is within the cost-
effectiveness threshold values recommended by WHO. Overall, model was sensitive 
to the changes in drug costs and patient weight. cOnclusiOns: TCZ+MTX incurred 
significantly higher costs compared to IFX+MTX, although ICER per achieved ACR70 
lays within the recommendations of WHO. Further research is necessary for other 
ACR rates. These findings may better inform decision makers regarding formulary 
inclusion and reimbursement in the treatment of RA patients in Kazakhstan.
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(BMD) testing with dual energy x-ray absorptiometry (DXA) and received five years 
alendronate therapy if the percent young adult mean (%YAM) for BMD was less 
than 70%. Lifelong drug therapy for secondary fracture prevention was assumed 
for patients who had a osteoporotic fracture. For the base-case analysis, we ran 
the model with different age groups (65-69, 70-74, and 75-79 years). Results: 
In the women aged 65-69 years, screening strategy incurred an additional life-
time cost of $1,486 per person and conferred an additional 0.029 QALY, resulting 
in an incremental cost-effectiveness ratio of $51,195per QALY gained. For those 
aged 70-74 and 75-79 years, ICER was estimated to be $23,375 and $17,742per 
QALY, respectively. Probabilistic sensitivity analysis showed that in women aged 
65-69,70-74 and 75-79 years, screening strategy was cost-effective in 48.9%, 58.9%, 
and 59.7% of the simulations, respectively, if society is willing to pay $50,000 per 
QALY. cOnclusiOns: Osteoporosis screening and treatment strategy would be 
cost-effective in the Japanese women aged ≥70 years.
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Objectives: While widely perceived as a successful procedure, discectomy surgery 
has a high failure rate over time. The overall risk of recurrent disc herniation varies 
between 2-18% in reported literature. The Barricaid® anular closure device was 
designed as an adjunct to lumbar limited microdiscectomy to block large anular 
defects while maintaining as much native nucleus within the disc space. Patients 
that are considered for anular closure have a minimum posterior disc height of 
5mm, and an intra-operatively measured anular defect between 5mm and 12mm 
wide. The aim of this study was determined as to assess the cost effectiveness of the 
use of Barricaid® in this group of patients in Turkey. MethOds: A simple decision 
analysis model was used to assess the cost effectiveness of the use of Barricaid®. 
The primary clinical endpoint was determined as the number of prevented rehernia-
tions. According to the literature, the use of Barricaid® reduced the number of 
reherniations by 18%. Resource utilization data were obtained via expert clinical 
opinion and included pre-op, post-op and follow-up costs, etc. Unit costs were taken 
from the Social Security Institution’s official price list. Results were presented as 
incremental cost/number of prevented reherniations. The comparison was made 
between using and not using the Barricaid®. Results: According to the results of 
the cost effectiveness analysis, the incremental number of prevented reherniation 
was 4.398 with Barricaid® and incremental cost was 119.343.000 TL. The ICER was 
within the limits of the threshold recommended by the World Health Organization 
with 27.136 TL. cOnclusiOns: Use of Barriciad® in lumbar discectomy surgery is 
a cost-effective treatment option in Turkey.
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Objectives: To evaluate the use of tocilizumab in Russian patients with systemic 
juvenile idiopathic arthritis (SJIA) in terms of cost-effectiveness and impact on 
social and economic burden of the disease. MethOds: The model was based on 
TENDER clinical study (De Benedetti F et al., 2012). First, a pharmacoeconomical 
cost-efficiency of tocilizumab and a standard basic therapy of SJIA were com-
pared. The analysis included direct medical costs in two comparable groups (1st 
with routine administration of methotrexate and prednisolone, and 2nd with 
tocilizumab prescribed in case of refractoriness to NSAID and glucocorticoster-
oids). The efficacy of therapies was evaluated according to ACR criteria. After that, 
the influence of tocilizumab on cost and burden of illness was assessed. The 
analysis included direct medical costs and government expenditures on hospi-
talization, work incapacity insurance, monthly social pensions, benefits for care 
for a disabled children below 18 y. o. and GDP losses. 12-week time horizon was 
adopted in the CEA model, and a 1-year horizon for the assessment of burden 
of illness. Results: The cost-effectiveness in terms of ACR 90 and 70 was 4 428 
262.96 and 2 952 175.31 RUB for the group of standard treatment, and 1 166 111.66 
and 615 218.74 RUB for tocilizumab group. Tocilizumab demonstrated the same 
benefits in terms of ACR 50, 30. Analysis of burden of illness revealed a different 
structure of financial expenditures in considered strategies: pharmacotherapy 
constituted > 50% costs in tocilizumab group, but hospitalization costs were 12 
times less than in standard therapy. Annual budget losses due to social burden of 
this disease were 426 144.63 RUB per patient in the group of standard treatment 
and 226 729.10 RUB in tocilizumab group. cOnclusiOns: The use of tocilizumab 
in SJIA is justified by better cost efficiency and reduced of social and economic 
losses of state budget connected with the burden of the disease.
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Objectives: The present study aims to estimate the cost-effectiveness of etaner-
cept compared to golimumab in the treatment of patients with Rheumatoid 
Arthritis (RA) in Portugal. MethOds: A model was adapted to assess the cost-
effectiveness of etanercept in the treatment of RA. We performed a comparison 
of the combination of etanercept + methotrexate and golimumab + methotrexate. 
Dosage of etanercept was 50mg on a weekly basis, whereas for golimumab it was 
50 mg once a month. The model is an individual simulation model and takes 
a lifetime perspective. Outcomes are expressed in QALYs, using the HAQ score 
€ 4,471 per event averted. Probabilistic and univariate sensitivity analyses were 
robust and confirmed results of the base case scenario. cOnclusiOns: This eco-
nomic evaluation modeling suggests that celecoxib may be considered as a cost-
effective alternative vs. t-NSAIDs in the treatment of osteoarthritis in daily practice 
in the Spanish NHS.
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Objectives: To estimate the cost-effectiveness of biologic disease modifying anti-
rheumatic drugs (bDMARDs) following failure of conventional disease modifying 
anti-rheumatic drugs (cDMARDs) in patients with severe or mild-to-severe active 
rheumatoid arthritis from a UK, NHS perspective, as part of an ongoing National 
Institute of Health and Care Excellence (NICE) appraisal. MethOds: Systematic 
review of clinical effectiveness of seven bDMARDs: abatacept; adalimumab; cer-
tolizumab pegol; etanercept; golimumab; infliximab; and tocilizumab. Network 
meta-analyses (NMA) of randomised controlled trials (RCTs) reporting European 
League Against Rheumatism (EULAR) response and for RCTs reporting American 
College of Rheumatology (ACR) outcome data. An individual patient model was 
constructed to estimate costs and outcomes in terms of quality adjusted life years 
(QALY). Large observational databases, published literature and the results of the 
NMAs were used to provide data for the model. Following failure of two cDMARDs 
two broad strategies were evaluated i) a bDMARD, followed by, if necessary, rituxi-
mab then tocilizumab then cDMARDs and ii) remaining on cDMARDs. Results: 
The estimated incremental costs per QALY of bDMARD strategies compared with 
a cDMARD alone strategy were typically over £50,000 regardless of the severity 
of rheumatoid arthritis or whether the EULAR or the ACR RCTs were used. The 
cost per QALY is greater for those who receive bDMARD monotherapy. One key 
parameter affecting the results was the estimated trajectory of HAQ progres-
sion whilst a patient received cDMARDs; using rates previously assumed in NICE 
appraisals reduced estimates to approximately £30,000. cOnclusiOns: bDMARDs 
are unlikely to be as cost-effective as has been estimated previously. The costs 
per QALYs generated within our base case analyses are greater than commonly 
reported cost-effective thresholds in England and Wales.
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Objectives: The study aims to assess the cost-effectiveness of telerehabilitation 
for Total Knee Arthroplasty (TKA) patients in Italy. TKA was performed 64,936 
times in Italy in 2012, reasonably leading to the same number of rehabilitation 
processes. The most recent cost analysis showed rehabilitation to account for Euro 
158 million per year. Therefore, new strategies aiming at optimizing resources 
and preserve patients’ wellbeing are claimed. MethOds: A four-state Markov 
model (successful TKA; revision; successful revision; death) forecasted costs 
and clinical outcome over 10 years (cycle length: 1 year) for 1,000 individuals 
undergoing usual care rehabilitation (UC) or a mixed UC-telerehabilitation (UC-T) 
program. Published literature provided transition probabilities and clinical out-
come (active knee flexion Range Of Motion-ROM); while UC and telerehabilitation 
costs were estimated through Italian tariffs and panel of experts. Each surgery 
was assumed to lead to rehabilitation or telerehabilitation, resulting in direct 
medical and indirect costs (human capital approach). Results were adjusted 
applying half-cycle correction method and discount rate of 3%. A Probabilistic 
Sensitivity Analysis described parameters uncertainty and results were reported 
using Incremental Cost-Effectiveness Ratios (ICER) from societal and Italian-NHS 
perspectives. Results: Expected mean health care costs for UC were 1,253.2€ /
patient over ten years, and UC-T costs were on average 33.7€ /patient higher (95%CI 
€ 10.8). ROM-degrees for UC and UC-T were respectively 24.5 and 26.8 (mean dif-
ference= 2.3, 95%CI 0.002). The resulting ICER was 14.5€ /ROM-degree (Italian-
NHS perspective). Adopting a societal perspective, UC-T was more effective yet 
appeared cheaper than UC (respectively 1,429 and 1,457€ /patient, mean differ-
ence -28/patient (95% CI € 10.8)). cOnclusiOns: Although the preliminary results 
have shown that UC-T could be a cost-saving procedure if societal perspective is 
adopted; these findings are uncertain due to the model assumptions. Therefore, 
further investigations with patient-level data and generic outcome measures 
(e. g. QALY) are required to draw definitive conclusions about cost-effectiveness 
in telerehabilitation.
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Objectives: The objective of this study was to estimate the cost-effectiveness of 
osteoporosis screening and treatment with alendronate in the Japanese women 
aged ≥65 years without a fragility fracture history. MethOds: A Markov model 
with ten health states (no event, seven types of post-fracture, bedridden, and 
death) was developed to predict lifetime costs and quality-adjusted life years 
(QALY) of screening and treatment strategy, comparing with no screening. In the 
screening arm, 1,000 hypothetical cohort experienced a bone mineral density 
